Figure 4
From: Targeting Mcl-1 by a small molecule NSC260594 for triple-negative breast cancer therapy
NSC260594 treatment reduces cancer stem cell (CSC) population in TNBCs. (A) MDA-MB231 Cells were treated with NSC260594 and detached with versene/0.48 mM EDTA. Cells were co-stained by fluorochrome-conjugated antibodies against CD44 (FITC) and CD24 (PE) at 4 °C in the dark for 20 min. The labelled cells were analyzed on a FACS Calibur, the results were analyzed by FlowJo software. (B) The population of CD44highCD24low cells in A was quantified. (C) MDA-MB 231 and (D) 4175 were treated with NSC260594 for 48 h, stem cell marker ALDH1/2 and ABC transporters ABCG2 were examined by western blot assay, vinculin was used as protein loading control. Data shown represent the mean ± SD from three independent experiments, each performed in triplicate. Statistically significant values of *p < 0.05, and **p < 0.01 were determined compared with the control.
